1939 results about "Pharmaceutical Aids" patented technology

The invention discloses a pharmaceutical composition containing melogabalin besylate and a preparation method of the pharmaceutical composition. Belongs to the technical field of pharmaceutical preparations. Comprising melogabalin besylate and pharmaceutically acceptable auxiliary materials, the pharmaceutically acceptable auxiliary materials comprise a filler, a disintegrating agent, an adhesive, an antioxidant and a lubricant, the antioxidant comprises vitamin E succinic acid polyethylene glycol ester, and the lubricant comprises vitamin E succinic acid polyethylene glycol ester. The melogabalin besylate as the active ingredient accounts for 2-15% by weight of the pharmaceutical composition, preferably 2-10% by weight of the pharmaceutical composition. According to the pharmaceutical composition, antioxidant particles are prepared by adopting a fluidized bed granulation process, raw material medicines, the antioxidant particles and other auxiliary materials are mixed, tableted and coated, an antioxidant comprises vitamin E succinic acid polyethylene glycol ester and tartaric acid, and the prepared tablet has good stability.

The invention relates to a dialkyl imidazole bionic lipid compound and a preparation method and application thereof.The structure of the dialkyl imidazole bionic lipid compound imitates natural phospholipid design, alkyl with no less than 10 carbon atoms is modified on the fourth site and the fifth site of imidazole, and primary amines with different alkyl chain lengths are modified on the second site; the dialkyl imidazole bionic lipid compound is mixed with a therapeutic drug and other auxiliary materials to prepare lipid nanoparticles loaded with the therapeutic drug, and the lipid nanoparticles can be used as a drug delivery system for preparation of brain-targeted drugs. The dialkyl imidazole bionic lipid has the function of dynamically regulating and controlling the blood-brain barrier, and can realize reversible opening of the blood-brain barrier; the formed drug-loaded lipid composition can pass through a blood brain barrier and well realize brain-targeted delivery of loaded therapeutic drugs; the drug-loaded lipid composition composed of the dialkyl imidazole bionic lipid belongs to a new generation of bionic nano-drug carriers, and provides a new strategy for realizing brain-targeted delivery of different types of drugs.

The invention relates to the technical field of medicine quality detection, and particularly discloses an optical detection method and system for the content of vitamin tablets. The method comprises the following steps: driving an optical fiber probe array to carry out three-dimensional multi-angle near-infrared scanning through a multi-axis mechanical arm, and collecting reflection spectrum data; a weighted spectrum is generated through derivative spectrum analysis and double evaluation, and auxiliary material noise is corrected and separated in combination with subspace projection and a dynamic kernel function; performing spectral vector projection and regression coefficient iterative optimization through an online PLS model, and synthesizing an error coefficient based on a four-level index retrieval standard library to perform dual-channel feedback; and finally, fusing the credibility weight to output a detection result of the binding confidence. The method realizes nondestructive and high-precision detection of the vitamin tablets, has the beneficial effects of multi-dimensional data fusion, dynamic error compensation and high model adaptability, and remarkably improves the detection accuracy and reliability.

The invention relates to a layered drug-loading microneedle patch as well as a preparation method and application thereof. The preparation method of the layered drug-loading microneedle patch comprises the following steps: S1, dissolving a drug and a soluble high-molecular polymer in a solvent according to a mass ratio of (2: 1)-(1: 12) to form a needle tip solution, then filling a needle tip cavity of a microneedle mold with the needle tip solution, drying, and removing redundant drug residues on the surface to form a drug-loading needle tip layer; and S2, filling a mold containing the drug-loading needle tip layer with a photocurable polymer, performing ultraviolet curing for 10-30 seconds under the wavelength of 365-405 nm, and then performing demolding to form a substrate layer, thereby obtaining the layered drug-loading microneedle patch. According to the method, one-time filling of the needle tip part is successfully achieved by combining needle tip auxiliary material proportion optimization, meanwhile, the curing process is rapid, the medicine utilization rate and the process stability are remarkably improved, the medicine stability is good, and the method is suitable for industrial production.

The invention discloses an efficient-dissolution dotenorad tablet and a preparation method thereof, and relates to the technical field of tablet preparation. The tablet consists of 5-20 parts of a dotenorad active component, 10-30 parts of a disintegrating agent, 40-70 parts of a filling agent, 0.5-5 parts of a surfactant, 0.5-3 parts of a lubricant, 1-5 parts of an adhesive and 0.5-1 part of an antioxidant. The preparation method comprises the following steps: premixing active components and auxiliary materials, carrying out high-shear wet granulation to form porous structure particles, carrying out precise temperature-control drying through a fluidized bed, carrying out micronization treatment to regulate the specific surface area of the particles, and finally, carrying out high-pressure tablet forming through a magnesium stearate / aerosil compound lubrication system. The dissolution rate of the tablet in a medium with the pH value of 6.8 for 15 minutes reaches 85% or above, meanwhile, long-term stability is achieved by inhibiting oxidative degradation, and the tablet has the dual advantages of quick effect taking and stable storage.

The present application relates to a kind of dihydrocarbylimidazole biomimetic lipid compound and its preparation method and application, dihydrocarbylimidazole biomimetic lipid compound structure imitates natural phospholipid design, modification is not less than 10 carbon atoms alkyl on the 4th and 5th of imidazole, and modification is different alkyl chain length primary amine on 2nd position;Dihydrocarbylimidazole biomimetic lipid compound is mixed with therapeutic drug and other adjuvant, can be prepared to be loaded in the lipid nanoparticle of therapeutic drug, can be used as drug delivery system for the preparation of brain-targeted drug.Dihydrocarbylimidazole biomimetic lipid has the function of dynamic control blood-brain barrier, can realize the reversible opening of blood-brain barrier;Formed drug-loaded lipid composition can cross blood-brain barrier and better realize the brain-targeted delivery of loaded therapeutic drug;Drug-loaded lipid composition consisting of dihydrocarbylimidazole biomimetic lipid belongs to a new generation of biomimetic nanomedicine carrier, provides new strategy for realizing the brain-targeted delivery of different kinds of drugs.

The invention discloses pulsatilla saponin B4-oleanolic acid self-assembled nanoparticles as well as preparation and application thereof, and relates to the technical field of pharmaceutical preparations. Inspired by compatibility and solubilization of traditional Chinese medicines, the pulsatilla saponin B4-oleanolic acid self-assembled nanoparticles (AB4-OA NPs) are prepared by taking natural active components, namely micromolecular pulsatilla saponin B4 and oleanolic acid, as raw materials; the oleanolic acid has the effects of promoting dissolution and resisting inflammation, the water solubility of the oleanolic acid is improved, the bioavailability is improved, and the anti-inflammatory effect of the oleanolic acid is enhanced. Experimental results show that the AB4-OA NPs can effectively improve the dissolution rate of the oleanolic acid, so that the bioavailability of the oleanolic acid is effectively improved, meanwhile, the AB4-OA NPs has a better anti-inflammatory effect, and the effect is better than that of a single drug with the same dosage. In addition, the synthetic preparation method is simple and convenient, has the advantages of nano-scale drugs, realizes auxiliary-material-free pure drug self-delivery, and improves the delivery efficiency.

The invention provides a composition capable of penetrating an intestinal barrier by oral administration. The composition contains a carrier or an auxiliary material of a targeted Microflod cell Dectin-1 receptor, and one or / and a plurality of medicinal components / components, wherein the carrier or the auxiliary material of the target Microflood cell Dectin-1 receptor is beta-glucan, and the carrier or the auxiliary material of the target Microflood cell Dectin-1 receptor is beta-glucan. The effective components / components are traditional Chinese medicine effective components / components, or / and probiotics, or / and chemical medicine components, or / and biological medicines. The invention relates to a composition capable of realizing oral administration and penetrating through an intestinal barrier, which is based on the discovery of the inventor that the composition reaches colon through gastrointestinal tracts, targets colon Microflood cells, is taken by the Microflood cells, penetrates through the intestinal barrier and enters immune tissue Colonic Patches of a colon submucosa. Based on the research, the composition disclosed by the invention can be used for treating various diseases, such as ulcerative colitis, Crohn's disease, colon cancer, rheumatoid arthritis or bacterial pneumonia after being orally taken and absorbed by rectum.

The invention discloses an application of isorhamnetin-3-O-neohesperidin in preparation of a medicine for preventing and / or treating benign prostatic hyperplasia. In-vitro experiments show that the isorhamnetin-3-O-neohesperidin can inhibit proliferation of prostatic hyperplasia cells, promote apoptosis of the prostatic hyperplasia cells and regulate inflammatory response of the prostatic hyperplasia cells, and rat experiments show that the isorhamnetin-3-O-neohesperidin can improve the hormone endocrine disorder condition of an animal model body, and can inhibit the prostatic hyperplasia cells and promote the prostatic hyperplasia cell apoptosis and regulate the inflammatory response of the prostatic hyperplasia cells. The anti-inflammatory ability of an animal model is enhanced, and the traditional Chinese medicine composition has a relatively good treatment effect on prostatic hyperplasia caused by testosterone propionate. The medicine for preventing and / or treating benign prostatic hyperplasia, provided by the invention, contains a pharmacodynamic dose of isorhamnetin-3-O-neohesperidin and a pharmaceutically acceptable carrier or auxiliary material, can be prepared into a medicine dosage form which is convenient for clinical use and can play an optimal curative effect, and has a relatively high clinical application value.

The invention discloses application of 4, 5-dialkyl imidazole cationic lipid in a drug brain delivery carrier, and belongs to the field of drug delivery. The 4-site and the 5-site of imidazole are respectively modified with alkyl with not less than 10 carbon atoms to form the 4, 5-dialkyl imidazole cationic lipid. The 1, 4, 5-dialkyl imidazole cationic lipid is mixed with a therapeutic drug and other lipid auxiliary materials to prepare drug-loaded lipid nanoparticles loaded with the therapeutic drug, and the drug-loaded lipid nanoparticles can be used as a drug delivery system for brain delivery of the therapeutic drug. The 1, 4, 5-dialkyl imidazole cationic lipid has the function of dynamically regulating and controlling opening and closing of a blood brain barrier, and reversible opening of the blood brain barrier can be achieved; the formed drug carrier can pass through a blood brain barrier and well realize brain delivery of loaded therapeutic drugs, and a new strategy is provided for brain delivery of different types of drugs.

The present invention relates to the technical field of pharmaceutical preparations, and specifically discloses a beclomethasone dipropionate suspension for inhalation and a preparation method thereof. The present invention uses polyethylene glycol hyaluronic acid as a surfactant, polysorbate 80 (II) as a wetting agent, and colloidal microcrystalline cellulose as a suspending agent, first prepares an auxiliary material solution containing part of the surfactant, the wetting agent and the suspending agent, and a drug solution of beclomethasone dipropionate and the surfactant, and then mixes the drug solution with the auxiliary material solution and homogenizes under high pressure to prepare the beclomethasone dipropionate suspension for inhalation. The prepared beclomethasone dipropionate suspension has excellent storage stability and effective lung deposition rate, effectively solves the potential harm to respiratory tissue caused by the use of a large amount of Tween 20 and Span-type surfactants in the original research, can achieve a good replacement for the original research product, and has a simple preparation process, good repeatability, and is easy to achieve industrialized large-scale production, and has a high value of promotion and application.

The invention discloses construction and application of an oral gel drug delivery system based on a yeast microcapsule, and belongs to the field of new auxiliary materials and new dosage forms of pharmaceutical preparations, the drug delivery system is composed of budesonide nanoparticles, the yeast microcapsule and gel, budesonide nanoparticles are prepared from budesonide and a polylactic acid-glycolic acid copolymer through a water-in-oil emulsification evaporation technology, yeast cell wall microcapsules are formed after content of yeast powder is removed, and the budesonide-loaded yeast microcapsules are prepared from the yeast microcapsules and the budesonide nanoparticles through stirring, ultrasonic treatment and freeze drying methods. The yeast cell wall microcapsule without contents is used as a carrier, so that the medicine is protected from being degraded by gastric acid, and the intestinal immune response is regulated by targeting intestinal related lymphatic tissues (GALT). The gel prepared by combining pectin can prolong the residence time of the drug in the intestinal tract, realizes continuous release, reduces the whole-body side effect of budesonide, and improves the treatment efficiency.

The invention relates to the technical field of biological medicine, in particular to a ferroptosis inhibition type phospholipid-like material and application thereof. The ferroptosis inhibition type phospholipid-like material is one of the following structural general formulas (1)-(5). The biomimetic phospholipid-like ferroptosis inhibitor has a long retention characteristic in main positions (cell membranes, endoplasmic reticulum and other organelle membranes) of cell ferroptosis, so that the ferroptosis inhibition efficiency is remarkably improved. The novel phospholipid-like material not only can be used as an active drug molecule, but also can be used as a pharmaceutic adjuvant for constructing drug delivery carriers such as lipidosome and micelle and implant coatings, and is suitable for various administration routes such as oral administration, injection and local administration. The novel biomimetic ferroptosis inhibitor can efficiently relieve cell ferroptosis and has a wide application prospect in the field of treating or retarding ferroptosis-related diseases.

The invention discloses a preparation method of perindopril amlodipine tablets, and belongs to the field of pharmacy. The perindopril amlodipine tablet is prepared from the following raw material medicines: arginine perindopril and amlodipine besylate and auxiliary materials: lactose, microcrystalline cellulose, hydrophobic colloidal silicon dioxide and magnesium stearate. The preparation method of the perindopril amlodipine tablet comprises the following steps: weighing according to the prescription amount, crushing and sieving the raw materials for pretreatment, sieving the whole particles of the auxiliary materials for pretreatment, premixing, feeding and total mixing, tabletting and the like. The prepared perindopril amlodipine tablet is relatively good in quality, high in stability and relatively few in waste products.

The invention discloses traditional Chinese medicine monomer self-assembled nanoparticles as well as a preparation method and application thereof, and relates to the technical field of pharmaceutical preparations. According to the prepared traditional Chinese medicine monomer self-assembled nanoparticles, namely ginsenoside Rg1-oleanolic acid self-assembled nanoparticles, the self-assembled structural characteristics of ginsenoside Rg1 are ingeniously utilized, the superficial area of the medicine can be effectively increased, the solubility of oleanolic acid can be improved, and therefore the bioavailability of oleanolic acid is effectively improved, and the anti-inflammatory effect of the oleanolic acid is further enhanced. And compared with a physical mixed medicine with the same dosage, the effect is more remarkable. Besides, the preparation method is simple and easy to implement, not only has the advantages of nanoscale drugs, but also realizes self-delivery of pure drugs without auxiliary materials, and greatly improves the delivery efficiency of the drugs.

The invention discloses a rod core, a punching type implant as well as a preparation method and application of the punching type implant. The rod core comprises a drug-containing layer, and the drug-containing layer comprises active drugs and auxiliary materials. The auxiliary materials comprise sustained and controlled release auxiliary materials; the molecular weight of the sustained and controlled release auxiliary material is 10000-10000 thousands; the medicine-adjuvant ratio is 1: (0.01-100); the medicine-adjuvant ratio represents the mass ratio of the active medicine to the adjuvant in the medicine-containing layer; optionally, the rod core of the punching type implant also comprises a boosting layer compounded on the medicine-containing layer. The implant provided by the invention can be suitable for most drugs, and can realize long-acting release of the drugs.

The invention discloses a pharmaceutical preparation of a protein kinase inhibitor citrate as well as a preparation method and application of the pharmaceutical preparation. The pharmaceutical preparation comprises citrate of a protein kinase CDK4 / 6 inhibitor and auxiliary materials including a filler, a disintegrating agent, an adhesive, a wetting agent, a glidant and a lubricant. The protein kinase inhibitor citrate pharmaceutical preparation has the advantages of being good in quality, high in stability, high in dissolution rate, simple in preparation method, controllable in quality and the like.

The present invention provides a pharmaceutical composition, the composition comprises a therapeutically effective amount of bumetanib, one or more specific antioxidants and other necessary one or more pharmaceutically acceptable pharmaceutic adjuvants, and the specific antioxidants are selected from one or more of fat-soluble vitamin C derivatives or phenolic antioxidants. In addition, the invention also discloses a method for improving the stability of the bumetanib pharmaceutical composition. According to the technical scheme, the problems of generation and growth of N-nitroso bumetanib and other related substances in the production and storage process of the bumetanib solid preparation are effectively solved, and the drug stability and the medication safety are remarkably improved.

The invention belongs to the technical field of pharmaceutical analysis, and relates to a method for detecting the content of povidone K30. According to the method, the content of povidone K30 in the medicinal preparation is detected by adopting a high performance liquid chromatography; detection conditions of the high performance liquid chromatography are as follows: a chromatographic column is a C18-AQ column; a mobile phase is a phosphate solution. The method has the characteristics of high accuracy, strong specificity and the like for detecting the content of povidone K30 in the pharmaceutical preparation, can overcome the interference of other auxiliary materials in the pharmaceutical preparation, and has important application value in development and consistency evaluation of the pharmaceutical preparation.

The invention belongs to the technical field of biological medicines, and particularly relates to an umbilical cord mesenchymal stem cell preparation and application thereof in treating prostate diseases. According to the umbilical cord mesenchymal stem cell preparation, the umbilical cord mesenchymal stem cells of the third generation to the sixth generation and the neurofilament peptide serve as active components, pharmaceutically acceptable auxiliary materials are matched, the prostate index can be remarkably reduced, the concentration of PACP and SRD5A2 can be reduced, and the umbilical cord mesenchymal stem cell preparation has a remarkable curative effect on prostatic hyperplasia. And the umbilical cord mesenchymal stem cells of the third generation to the sixth generation and the neurofilament peptide supplement each other and have a synergistic effect, so that a remarkable progress is generated.

The invention relates to the technical field of oral membranes, in particular to a multilayer oral membrane and a preparation method thereof. The invention provides an oral membrane composition, which comprises semeglutide and pharmaceutically acceptable auxiliary materials, and is characterized in that the composition is formed by combining a drug-containing biological adhesion layer and a backing layer, and the backing layer mainly comprises a membrane forming material, a solvent and a plasticizer; the drug-containing biological adhesion layer mainly comprises semeglutide, a film-forming material, an adhesive, a pH regulator, a flavoring agent and a solvent. By preparing the double-layer oral membrane, the semeglutide is administrated through the oral cavity, and after the insoluble or slowly eroded / dissolved backing layer (preventing saliva from dissolving the medicine) and the adhesive layer containing the main medicine are combined together, the one-way delivery of the main medicine can be realized; through experiments, it is accidentally found that when temperature-sensitive materials such as poloxamer are added to be combined with a conventional adhesive for use, the residence time of the medicine in the oral mucosa can be remarkably prolonged, the curative effect of the medicine is improved, and the main mechanism is that after the medicine is administered, in the oral temperature environment, after the medicine makes contact with mucus on the surface of the oral mucosa, the oral mucosa does not adhere to the oral mucosa. And after the entanglement and piling effects among poloxamer micelles are intensified to form gel, the gel and a conventional adhesive are cooperated to improve the adhesion between the oral membrane and the oral mucosa. Besides, the medicine can be removed at any time, blood sugar can be better controlled, T2DM complications can be better reduced, a more ideal taking mode is provided for weight loss patients, and a new administration mode is provided for reducing blood sugar and reducing weight. The prepared oral cavity membrane is small in size, light in weight, thin, convenient to apply, carry and transport, safe and environmentally friendly to use and capable of meeting the requirements of old people and travelers.

The invention relates to the technical field of medicines, in particular to application of an active ingredient xanthohumol (XAN) derived from a traditional Chinese medicine humulus lupulus in preparation of medicines for reducing uric acid and resisting gout, and the xanthohumol (XAN) can be prepared into various oral preparations, injection preparations and external preparations with the assistance of pharmaceutically acceptable auxiliary materials and has good development and application prospects. The inventor finds that the xanthohumol has relatively strong effects of reducing blood uric acid, resisting inflammation, resisting bone damage and the like, and the mechanism of the effect of reducing the blood uric acid is that the activity of xanthine oxidase is inhibited so as to reduce the generation of uric acid, and the renal function of an organism is improved so as to enhance uric acid excretion; according to the anti-inflammatory effect, the inflammatory reaction is relieved mainly by down-regulating the levels of inflammatory factors such as IL-1beta, IL-6, TNF alpha and PEG2; the mechanism for resisting gout bone damage is realized through the fact that RANKL / OPG / RANK signal pathway participates in bone metabolism regulation.

The invention belongs to the technical field of plant extracts, and particularly relates to application of a carob bean extract in a medicine for improving glycometabolism / female polycystic ovarian syndrome. The invention discloses a pharmaceutical composition for improving glycometabolism female polycystic ovarian syndrome. The pharmaceutical composition is prepared from a carob bean extract, baicalein, cedrol, bioactive peptide, biological polysaccharide and auxiliary materials. The composition disclosed by the invention has the effects of reducing blood sugar, reducing blood fat and improving an insulin function, and also has the effects of resisting oxidation, enhancing immunity and the like, and the substances are combined for use, so that a synergistic interaction effect is achieved, and the effect of improving / treating the abnormal glucose metabolism related female polycystic ovarian syndrome is further improved.

The invention discloses a probiotic preparation, the preparation is composed of an effective amount of anti-TGF-beta1 monoclonal antibody, an effective amount of probiotics and other auxiliary materials, and amino acid sequences of a heavy chain variable region and a light chain variable region of the anti-TGF-beta1 monoclonal antibody are shown as SEQ ID NO.1 and SEQ ID NO.2. The invention further discloses a preparation method of the probiotic preparation. The probiotic preparation disclosed by the invention can effectively improve sleep quality and solve the problem of insomnia generally faced by modern people. By combining the probiotics with the anti-TGF-beta1 monoclonal antibody, the preparation not only can regulate the intestinal microecology, but also can promote sleep by influencing the nervous system, and has a remarkable improvement effect. Meanwhile, the preparation method disclosed by the invention is simple, economical and suitable for large-scale production, and has a good market application prospect.

The invention belongs to the technical field of medicine mixing, and discloses a multifunctional mixing device for tablet medicine production and a mixing method.The multifunctional mixing device comprises a mixing tank body, a second servo motor is fixed to the bottom end of the mixing tank body, a motor connecting rod is fixed to the top end of the second servo motor, and a driving defoaming mechanism is arranged at the top end of the mixing tank body; through cooperation of a stirring barrel, a limiting sleeve, a second connecting rod and other structures, when the rotating speeds of a first servo motor and a second servo motor are different, the second connecting rod makes contact with the long end of an extrusion disc and then shrinks inwards, and after passing, a third reset spring resets the second connecting rod; furthermore, when the raw materials pass through a transmission blade, the transmission blade is driven to rotate so as to drive a third connecting rod to rotate, so that the vibration effect is further improved; therefore, the aim of conveniently improving the mixing effect when the device mixes the medicine raw materials and the auxiliary materials is achieved.

A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.

The invention provides a medicine composition containing vinloxacin hydrochloride. The medicine composition comprises a quick-release pellet and a sustained-release pellet. The pharmaceutical composition provided by the invention has the advantages of good stability, capability of simultaneously meeting the specific requirement on in-vitro dissolution of the viloxin hydrochloride, small variety and dosage of auxiliary materials, higher safety and suitability for preparation of a preparation. And the protective layer is sprayed on the outer surface of the sustained-release layer, so that the advantages of weakening the electrostatic interaction of the pellets and preventing the particles from caking in the aging process are further achieved. In addition, the invention also provides a preparation method of the pharmaceutical composition, and the method has the advantages of high drug application rate, less fine powder, no filter bag and spray gun head blockage phenomenon, and suitableness for industrial production and application.

The invention provides a novel anti-cancer drug TNBG-sugar conjugate as well as preparation and application thereof, and belongs to the field of chemical medicines. The conjugates are compounds as shown in a formula I and a formula IV, or salts or stereoisomers thereof. The anticancer drug TNBG-sugar conjugate and a preparation prepared from the anticancer drug TNBG-sugar conjugate matched with appropriate auxiliary materials or auxiliary components have a good inhibition effect on cells of cancers such as lung cancer and liver cancer, are low in toxicity or basically non-toxic to normal cells, can be used for preventing and treating the cancers such as the lung cancer and the liver cancer, and have a good application prospect.

The invention discloses a coenzyme Q10-containing medicine for improving heart activity and a preparation method thereof, and particularly belongs to the technical field of biological medicines. The medicine comprises functional components and auxiliary materials, wherein the functional components comprise a cactus extract, a calligonum mongolicum extract, an astragalus membranaceus extract, a sea-buckthorn extract and coenzyme Q10; the hypoxia survival time and the load-bearing swimming time of mice can be remarkably prolonged through low, medium and high dose groups of the medicine for improving the heart vitality, the requirement of fatigue caused by high labor intensity for oxygen is further met by enhancing the immunity of the organism, supply of nutrient substances to the brain, the heart, the bones and the muscles of the organism is enhanced, and the effect of improving the heart vitality is achieved. The composition can regulate the activity of central nervous system, promote the normal operation of the body circulation system, relieve and eliminate fatigue and damage to the body caused by fatigue and chronic fatigue, and quickly recover physical strength.

The invention relates to the field of biomedical application of inorganic materials, in particular to application of lanthanum carbonate in preparation of drugs for resisting liver cirrhosis and inhibiting liver inflammations, the drugs comprise lanthanum carbonate and pharmaceutically acceptable auxiliary materials, the drugs are ground and then mixed with food to prepare a drug mixture, and the drug mixture is prepared into the drug for resisting liver cirrhosis and inhibiting liver inflammations. The mass ratio of the lanthanum carbonate in the medicine mixture is 1-10%, and the mechanism of the lanthanum carbonate for treating the liver cirrhosis is as follows: interference or blocking of activation and proliferation of hepatic stellate cells, inhibition of extracellular matrix generation and promotion of extracellular matrix degradation. According to the invention, a rat liver cirrhosis model is constructed through chemical induction, and the effects of reversing liver cirrhosis and inhibiting liver inflammation are found when a rat is treated by taking lanthanum carbonate orally, so that a new candidate drug is provided for clinical treatment of liver cirrhosis.